Abstract
Prognosis of recurrent gastric cancer is very poor. Efforts to prolong survival of these patients with modern empirical chemotherapeutic and recently by adding biologically targeted agents have modestly prolonged overall survival. On the other hand, mean overall survival remains less than 10 months. 1–3 In a recent issue of the Annals of Surgical Oncology, Badgwell et al. explored whether surgery could improve oncological outcomes in patients with recurrent gastric or gastroesophageal cancer. 4 Overall, prognosis of gastric cancer, particularly in the West, is poor. Patients with early detected stage I disease have excellent outcome after adequate surgery. 5,6 For patients with stage II or IIIA/IIB survival results reported from Japan and Western countries are contradictory. Most recently, Sasako et al. reported excellent 5-year survival rates of 70% with standardized D2 surgery alone in a welldesigned and well-conducted multicenter randomized phase III trial for Japanese stage II/III patients. 7 The sur
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
